Essen. Evonik has increased production capacity for ThreAMINO® (L-Threonine) at Evonik Agroferm Zrt., a 100 percent subsidiary of the Group in Kaba (Hungary), to 30,000 metric tons. The plant expansion officially came on stream on November 22 in the presence of representatives of the Hungarian government.
"The expansion of the plant in Kaba is a milestone for the growth strategy of Evonik in the area of feed amino acids," says Dr. Stefan Mack, Head of Product Management in the Bioproducts Business Line of Evonik. "We now have a world-scale plant for ThreAMINO® with state-of-the-art technology."
The fermentation and processing capacity was also increased as part of the expansion. Thanks to state-of-the-art membrane filtration and crystallization technologies, the yield achieved in the process has also increased. The additional quantities enable Evonik to meet the increasing demand for L-Threonine (feed grade 98.5 per cent) and to contribute to efficient animal nutrition.
L-Threonine, which Evonik markets under the brand name ThreAMINO®, is an essential amino acid that the body cannot produce itself. The animals therefore have to consume it with the feed. An optimal threonine content improves feed intake, weight gain, and the nutritional value of the feed. In contrast, nitrogen release is reduced because the crude protein content of the feed is balanced out according to the nutritional requirement of the animals.
Evonik is the only company in the world that produces and sells all four essential amino acids used in advanced animal nutrition: MetAMINO® (DL-Methionine), Biolys® (L-Lysine-Source), ThreAMINO® (L-Threonine) and TrypAMINO® (L-Tryptophan).
Evonik offers innovative products and services in more than one hundred countries and thus makes a significant contribution to customer cost efficiency as well as to a healthy and environmentally friendly animal feed.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of
the company form the heart of Evonik’s corporate strategy. Its activities focus on
the key megatrends health, nutrition, resource efficiency and globalization. Evonik
benefits specifically from its innovative prowess and integrated technology
Evonik is active in over 100 countries around the world. In fiscal 2012 more than
33,000 employees generated sales of around €13.4 billion and an operating profit
(adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).
In so far as forecasts or expectations are expressed in this press release or where our
statements concern the future, these forecasts, expectations or statements may involve
known or unknown risks and uncertainties. Actual results or developments may vary,
depending on changes in the operating environment. Neither Evonik Industries AG nor its
group companies assume an obligation to update the forecasts, expectations or statements contained in this release.